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Introduction: CD4+CD25+Foxp3+ regulatory T (Treg) cell depletion has been reported in sys-
temic lupus erythematosus (SLE) and, recently, in primary antiphospholipid syndrome 
(APS); the issue has not been studied in SLE patients with secondary APS (SLE/APS) so far. 
Objective: To quantify total lymphocytes, Treg cells, CD3+CD19– T cells and CD3–CD19+ B cells 
in SLE/APS patients and healthy controls. 
Methods: Cell subtypes underwent immunophenotyping using specific monoclonal antibod-
ies (anti-CD3 CY5, anti-CD4 FITC, anti-CD25, anti-Foxp3, anti-CD19 PE) and flow cytometry. 
Results: Twenty-five patients with SLE/APS (mean age 43.5 years, 96% females, 96% cauca-
sians, mean duration of disease 9.87 years, mean SLEDAI 10 ± 5.77) and 25 age and sex-
matched controls entered the study. It was realized that the numbers of Treg and CD3–
CD19+ B cells were significantly lower in SLE/APS patients than in controls (all p < 0.05). Treg 
and CD3–CD19+ B cells remained numerically low after controlling (ANCOVA) for percentage 
of total lymphocytes (p < 0.05). Decreasing levels of circulating Treg and CD3–CD19+ B cells 
correlated to higher scores of lupus activity (rs = -0.75, p < 0.0001; rs = -0.46, p = 0.021, re-
spectively). Number of Treg cells and CD3–CD19+ B lymphocytes did not significantly differ 
in users or nonusers of chloroquine, azathioprine and corticosteroids (all p > 0.05). 
Conclusions: In this preliminary study, patients with SLE and secondary APS showed deple-
tion of Treg and CD3–CD19+ B cells; decreasing numbers of both subtypes correlated to a 
higher SLEDAI. Treg cells depletion might contribute to the autoimmune lesion seen in 
patients with SLE/APS. The reduced number of CD3–CD19+ B cells seen in these patients 
deserves more studies in order to get further elucidation.
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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Pacientes com lúpus eritematoso sistêmico e síndrome antifosfolípide 
secundária possuem números reduzidos de células B CD4+ CD25+ 
Foxp3+ (células Treg) e células B CD3– CD19+ circulantes
Palavras-chave:
Lúpus eritematoso sistêmico (LES)
Síndrome antifosfolípide 
secundária (SAFS)
Células Treg 
Células B CD3– CD19+
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Introdução: A depleção de células T CD4+ CD25+ Foxp3+ regulatórias (células Treg) foi des crita 
em pacientes com lúpus eritematoso sistêmico (LES) e, recentemente, na síndrome antifosfo-
lípide (SAF) primária; até o momento, o tópico não tinha sido estudado em pacientes com LES 
e com SAF secundária (LES/SAFS).
Objetivo: Quantificar linfócitos totais, células Treg, células T CD3+ CD19– e células B CD3– CD19+ 
em pacientes com LES/SAF e em controles saudáveis.
Métodos: Subtipos celulares foram imunofenotipados utilizando anticorpos monoclonais espe-
cíficos (anti-CD3CY5, anti-CD4FITC, anti-CD25, anti-Foxp3, anti-CD19PE) e citometria de fluxo.
Resultados: Participaram do estudo 25 pacientes com LES/SAF (média de idade 43,5 anos, 96% 
mulheres, 96% da raça branca, duração média da doença 9,87 anos, SLEDAI médio 10±5,77) e 
25 controles compatibilizados para idade e gênero. Foi constatado que os números de células 
Treg e de células B CD3– CD19+ estavam significativamente mais baixos em pacientes com LES/
SAF, em comparação com controles (todos p<0,05). As células Treg e as células B CD3- CD19+ 
permaneceram numericamente baixas em seguida ao controle (ANCOVA) para percentual de 
linfócitos totais (p<0,05). Níveis decrescentes de células Treg e células B CD3- CD19+ circulantes 
tiveram correlação com escores mais elevados de atividade lúpica (rs=-0,75, p<0,0001; rs=-0,46, 
p=0,021, respectivamente). Os números de células Treg e de células B CD3- CD19+ não diferiam 
significativamente em usuários ou não usuários de cloroquina, azatioprina e corticosteroides 
(todos p>0,05).
Conclusões: Nesse estudo preliminar, pacientes com LES e com SAF secundária demonstraram 
depleção de células Treg e de células B CD3- CD19+; a redução numérica dos dois subtipos teve 
correlação com aumento de SLEDAI. A depleção de células Treg pode contribuir para a lesão au-
toimune observada em pacientes com LES/SAFS. O número reduzido de células B CD3- CD19+ 
observado nesses pacientes está a merecer estudos objetivando um aprofundamento em sua 
elucidação.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Systemic lupus erythematosus (SLE) is a multiorganic disease 
characterized by immune dysregulation; loss of tolerance to 
self-antigens leads to formation of immune complexes.1 Re-
cent data in both human SLE and mouse models have high-
lighted the role of type I interferon’s (α/β) in the initiation and 
perpetuation of the disease.2
Individuals with SLE are more susceptible to thrombosis 
than the general population, and the antiphospholipid syn-
drome (APS) is a well-known risk factor for vascular obstruc-
tion in such patients.3 The reason why patients with SLE and 
APS produce pathogenic antiphospholipid (aPL) antibodies 
has been a matter of intense debate.
CD4+CD25+Foxp3+ regulatory T (Treg) cells are a distinct 
thymically derived or inducible subset of T cells with unique 
immunosuppressive abilities. Quantitative or functional im-
pairment of Treg lymphocytes seems to direct the immune 
system toward autoimmunity.4 It is frequently observed an 
imbalance between IL-17 producing T helper (Th17) and Treg 
cells during the course of SLE, with marked impairment of the 
Treg subset.5 It is noteworthy that the blockage of Treg cells by 
interferon-α-producing antigen presenting cells may contrib-
ute to loss of peripheral tolerance in SLE.6
A CD4+CD25+Foxp3+ Treg cell dysfunction has been docu-
mented in a number of autoimmune disorders.7 In SLE cases, 
most studies have shown decreased number of circulating 
Tregs in active disease, but data are still conflicting.8
B lymphocytes, in turn, are pivotal cells in SLE; they are 
linked to antigen-presentation, autoantibody synthesis and 
cytokine production. It is noteworthy that a distinct subset 
of B cells shown to exert immunosuppressive effects;9 these 
IL-10-producers and regulatory-B cells, knowingly able to sup-
press T helper cells differentiation, appear to be functionally 
impaired in SLE patients.10
Considering the importance of the interplay of T, Treg cells 
and B lymphocytes in the immunopathogenesis of SLE (5-7; 
9,10) we set up to originally quantify total lymphocytes, Treg 
cells, CD3+CD19– T cells and CD3–CD19+ B cells in a Brazilian 
survey of patients with SLE/ secondary APS (SLE/APS) and 
healthy controls.
Material and methods
This cross-sectional study included patients with SLE and 
history of secondary APS from our Outpatient Lupus Clinic. 
Clinical and laboratory diagnosis of SLE were based on the 
American College of Rheumatology 1997 criteria,11 while the 
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Sidney 2006 criteria was utilized to diagnose APS.12 Lupus ac-
tivity was assessed by the systemic lupus erythematosus dis-
ease activity index, SLEDAI.13 
The exclusion criteria were as follows: 1) age below 16 
years; 2) infective endocarditis or other current infections; 3) 
diabetes mellitus; 4) neoplasms (current or past); and 5) infec-
tion by human immunodeficiency virus or Treponema pallidum. 
The control group comprised healthy individuals aged more 
than 16 years-old, matched by age and sex, and with no APS, 
connective tissue disorders, neoplasms or current infections. 
Clinical and demographic data were obtained from a chart 
review and interview with patients or family after informed 
consent. The study was approved by the local ethics commit-
tee.
Cell subtypes underwent immunophenotyping using the 
specific monoclonal antibodies anti-CD3CY5, anti-CD4 FITC, 
anti-CD25, anti-Foxp3 and anti-CD19 PE (Biosciences, San 
Jose, CA, USA) and identified by multicolor flow cytometry.14 
Quantitative statistical analysis was performed using SPSS 
17.0 software (SPSS Inc, Chicago, IL, USA). The significance 
level was set at a = 0.05 (two-tailed). The results were shown 
as means and standard deviation or by absolute and relative 
frequencies. The statistical analysis was performed by Stu-
dent’s t test and the Mann-Whitney test for the continuous 
variables, and chi-square or Fisher’s exact test for categorical 
variables. The Pearson test was utilized to correlate circulat-
ing cell subtypes with the SLEDAI. An analysis of covariance 
(ANCOVA) was performed to evaluate relationships between 
variables.
Results
Twenty-five patients with SLE/APS and 25 healthy controls 
entered the study. Middle-aged (mean age 43.5 years) fe-
males (96%) highly predominated in our SLE/APS survey. 
Twenty-four patients (96%) were caucasians. Mean duration 
of the disease was 9.87 years, and the average SLEDAI score 
was 10 ± 5.77. At the moment of evaluation, arthritis (36%), 
oral ulcers (32%), malar rash (24%), seizures (16%), nephri-
tis (12%), and leukopenia (8%) were the most frequent SLE 
manifestations. All patients had antinuclear antibodies, 
and 40% were positive for anti-dsDNA. Low complement 
levels were seen in 8% of patients.
Regarding the APS clinical features, deep vein thrombo-
sis (DVT) was seen in 15 patients (60%), while fetal losses 
(so considered after 12 weeks of pregnancy) occurred in 
6 patients (24%). Optic neuritis was seen in 4 cases (16%). 
Stroke and miscarriages were each diagnosed in 3 cases 
(12%). Moderate or high levels of anticardiolipin (aCL) an-
tibodies were detected in 21 patients (84%), whereas  lupus 
anticoagulant was present in 9 patients (36%). Fourteen pa-
tients (56%) were on oral anticoagulation regime with war-
farin, and the remaining was being treated with low-dose 
aspirin. 
Chloroquine, azathioprine and corticosteroids were be-
ing utilized by 9 patients (36%), 5 patients (20%) and 16 pa-
tients (64%), respectively.
Table 1 compares demographic aspects and lymphocyte 
subsets of SLE/APS patients and controls. Both groups were 
homogenous regarding age, gender and race. The mean 
number of CD4+CD25+Foxp3+ Treg cells and CD3–CD19+ B 
cells were significantly lower in patients with SLE/APS 
when compared to controls. The mean number of total lym-
phocytes, CD3+CD19– T cells and CD4+CD25+ lymphocytes 
did not significantly differ between groups. 
The SLE/APS patients were maintaining a significant-
ly lower number of Treg cells after the control (ANCOVA) 
for percentage of total lymphocytes (F = 28.50, p < 0.0001). 
The FoxP3 expression in CD4+CD25+ cells, as estimated by 
mean fluorescence intensity, did not differ in SLE/APS pa-
tients and controls (2660.55 ± 1044.06 vs 2470,65 ± 1732.87; 
p = 0.67; respectively). Patients with SLE/APS persisted with 
significantly lower percentage of CD3–CD19+ B cells after 
controlling for total lymphocytes (F = 13.17; p = 0.002).
Fig. 1 shows the distribution of total lymphocytes, 
CD4+CD25+Foxp3+ Treg cells and CD3–CD19+ B lymphocytes 
in SLE/APS patients as compared to controls.
The Pearson test for correlation of circulating Treg and 
CD3–CD19+ B lymphocytes with the SLEDAI is shown in 
Fig. 2. A significant negative correlation of both cell sub-
types with the SLEDAI was obtained, indicating that a lower 
number of Treg and CD3–CD19+ B cells were linked to in-
creasing scores of lupus activity. 
Table 1 – Demographic data and lymphocyte subset in 25 patients with systemic lupus erythematosus/secondary 
antiphospholipid syndrome (SLE/APS) and 25 healthy controls
SLE/APS Controls p
(n = 25) (n = 25)
Mean age (years ±SD) 43.5 ± 12.84 43.80 ± 8,45 0.93a
Females 24 (96%) 24 (96%) 1.00a
Caucasians 24 (96%) 24 (96%) 1,00a
Total lymphocytes 29.42 ± 4.57% 2227.86±528.83 cells/μL 32.2 ± 2.49% 2523.60±528.83 cells/μL 0.13b
CD3+CD19– T lymphocytes 73.72 ± 8.34% 1522.52±527.20 cells/μL 73.64 ± 7.70% 858.38±194.32 cells/μL 0,100b
CD4+CD25+ T lymphocytes 1.28 ± 0.89% 20.50±9.35 cells/μL 1.81 ± 0.80% 45.68±20.19 cells/μL 0,81b
CD4+CD25+Foxp3+ T 
lymphocytes 
0.74 ± 0.34% 21.61±12.70 cells/μL 1.83 ± 0.77% 46.18±19.43 cells/μL <0.0001b
CD3–CD19+ B lymphocytes 5.71 ± 2.66 % 136.34±92.68 cells/μL 9.25 ± 3.00% 233.43±75.71 cells/μL 0.006b
SD, standard deviation. 
aChi-square test. 
bStudents t test.
244 R E V  B R A S  R E U M A T O L .  2 0 1 4 ; 5 4 ( 3 ) : 2 4 1 – 2 4 6
Levels of circulating Treg cells did not signifi cantly vary 
among users or nonusers of chloroquine, azathioprine and 
corticosteroids (p = 0.90; p = 0.76 and p = 0.29 in the chi-square 
test, respectively). Similarly, the number of CD3–CD19+ B cells 
did not signifi cantly differ in users on nonusers of these med-
icines (p = 0.462; p = 0.512 and p = 0.341 in the chi-square test, 
respectively).
When we compared cell subtypes selectively in 5 patients 
with inactive SLE/APS (SLEDAI < 4) and 25 healthy controls, 
only the CD3–CD19+ B population remained diminished in the 
fi rst group (5.37 ± 1.95% × 9.25 ± 3.00%; p = 0.003; Student’s t 
test).
Discussion
A number of reports have accounted for a decrease of Treg 
cells in patients with SLE.15-17 As far as we are aware, this study 
is the fi rst to approach circulating Treg cells and B lympho-
cytes in Brazilian patients with SLE and secondary APS. Our 
survey included predominantly middle-aged white females 
with high SLEDAI, and mean disease duration of approxi-
mately a decade. Arthritis and oral ulcers were the prominent 
SLE fi ndings, while DVT and aCL antibodies were cardinal APS 
features. 
We have found a decreased number of circulating CD3–
CD19+ B cells in our SLE/APS patients when compared to con-
trols. It is important to say that there was no association of 
CD3–CD19+ B cell count with intake of chloroquine, azathio-
prine and steroids. The reasons for this B cell decrease in SLE/
APS patients are nebulous, but an explanation could be auto-
antibodies directed to B lymphocytes or intrinsic defects of B 
cell subsets. The fact that B cell depletion was confi rmed even 
in the 5 patients with inactive SLE might support the latter. 
We could only suppose the hypothesis that the population 
with B cells depletion is the IL-10 producer subset with im-
munosuppressive properties. It is noteworthy that competent 
B cells seem to be important to trigger Treg activity, as shown 
in patients with common variable immunodefi ciency18.
Reduced numbers of circulating CD4+CD25+Foxp3+ Treg cells 
were seen in our SLE/APS patients as compared to controls. As 
occurred the with the B cell subtype, Treg cells depletion was 
confi rmed after controlling (ANCOVA) for total lymphocyte 
count. Decreasing levels of circulating Treg cells, just as seen 
with the CD3–CD19+ B subset, were correlated with higher 
scores of disease activity. Diminished levels of Treg cells have 
been associated with active SLE19,20, but other reports21,22 ques-
tioned this fi nding. In our study, Treg cells depletion could be 
representative of an intrinsic defect related to previous SLE/
APS, or current SLE activity. Patients with inactive SLE did not 
show Treg reduction, which favors the second hypothesis. It 
is worthy of note that there was no association between Treg 
Fig. 2 – Pearson correlation of circulating Treg cells (A) 
and CD3–CD19+ B cells (B) with lupus activity assessed by 
the systemic lupus erythematosus disease activity index 
(SLEDAI). *Student’s t test 
Fig. 1 – Graphical distribution of total lymphocytes 
(A), CD4+CD25+Foxp3+ Treg cells (B) and CD3–CD19+ B 
cells (C) in controls and patients with systemic lupus 
erythematosus/secondary antiphospholipid syndrome 
(SLE/APS).*Students t-test.
rs=-0.75, p<0.0001*
rs=-0.46, p=0.021*
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cells decrease and the intake of chloroquine, azathioprine or 
steroids in our patients either.
Our group recently reported low levels of circulating Treg 
and also of CD3–CD19+ B cells in patients with primary APS23. 
These data, combined with the current study, imply that de-
pletion of both subsets occurs in APS populations as a whole. 
If this assumption will be confirmed, the Treg cells decrease 
may comprise one of the immune mechanisms leading to 
pathogenic aPL responses in primary or secondary APS. Nev-
ertheless, it should be considered that Treg cells decrease in 
our SLE/APS patients seemed to relate more to SLE activity 
than any other particular factor.
Recent data disclosed that any quantitative analysis of 
Tregs in patients with autoimmune disorders have to be seen 
with some caution. The reg cells show formidable plastic-
ity and comprise a heterogeneous population of suppressive 
cells, non-functional Treg cells and IL-17A-producing Treg 
cells acting as effector T lymphocytes. Thus, the simple nu-
meric count of Tregs might not be truly representative of their 
functional status.24
Some other limitations of our study must be mentioned. 
Even though the majority of our patients showed active SLE, 
the APS thrombotic manifestations were not current; newer 
studies should investigate the biological function of Treg cells 
and B lymphocytes during the thrombotic event and also in a 
longitudinal analysis. Given the small sample, we could not 
subgroup patients by SLE/APS features or drug dosage. The 
small number of patients with inactive SLE restricted the sta-
tistical power of the article. The same way, the lack of com-
parison between patients with SLE and without APS limited 
our conclusions. 
Up to date, the treatments of SLE and APS have been rea-
soned in immunosuppression and anticoagulation, respec-
tively. A direct immunomodulatory approach shifting the bal-
ance to favor Treg cells is being tried with autologous Treg cell 
therapy in type-1 diabetes,25 and such intervention might be 
promising for SLE and APS as well. Recently, it was noticed 
that Treg cells were able to prolong the interval of remission 
induced by conventional cytostatic drugs in (NZB × NZW) F1 
lupus mice.26
Although many questions concerning the pathogenesis 
of SLE and APS remain undefined, it is possible that the pro-
gression of the disease results from a breakdown in Treg-de-
pendent peripheral self-tolerance. In this context, Treg-based 
immunotherapy might have a place in the maintenance of 
disease remission in this group of patients.
In summary, this preliminary study demonstrated im-
paired numbers of CD4+CD25+Foxp3+ Treg cells and CD3–CD19+ 
B lymphocytes in Brazilian patients with SLE and secondary 
APS. Lower cell counts were seen in patients with higher SLE 
activity. Future studies shall confirm if the decrease of Treg 
cell levels is connected to the abnormal immune response 
seen in SLE/APS. The decrease of CD3–CD19+ B cells seen in 
these patients, and potentially linked to Treg dysfunction, also 
justifies new studies in order to search for more clarifications.
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